I.O. Samofalov
Research Subjects
Research Interests
I.O. Samofalov has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Marharyta Kalenichenko
National Aerospace University «Kharkiv Aviation Institute
1 shared publication - N. V. Bilozor1 shared publication
- O.O. Korolev1 shared publication
- Serhii Volodymyrovych Artiukh
Державна установа «Інститут медичної радіології та онкології ім. С.П. Григорʼєва Національної академії медичних наук України», Харків, Україна
1 shared publication - Yu.YU. Makhmudov
КНП «Обласний центр онкології
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 34 (1)
CT-guided interstitial high-dose-rate brachytherapy of the prostate: a clinical case
Background. Prostate cancer is characterized by a low α/β ratio, supporting the use of hypofractionated treatment regimens, particularly high-dose-rate (HDR) brachytherapy. However, the application of CT guidance in this setting remains limited and technically challenging. Purpose. – the aim of this study is to present a case of non-standard high-dose- rate (HDR) prostate brachytherapy in a patient with absence of the rectum. Materials and Methods. We present a clinical case of a patient born in 1975 with metachronous malignancies: prostate cancer cT2N0M0 (stage II, Gleason score 4+5=9) on the background of previously treated stage III colorectal cancer following multi- modal therapy. Multiparametric MRI demonstrated multifocal PI-RADS 4 lesions. Interstitial high-dose-rate (HDR) brachytherapy was delivered as a single-fraction treatment (19 Gy) to the entire prostate using 14 applicators under CT guidance. Results. Adequate PTV coverage was achieved (D90 = 19.7 Gy, D95 = 17.3 Gy) with compliance to dose constraints for organs at risk (urethra D2cc = 18 Gy, <95%). The calculated equivalent dose in 2 Gy fractions (EQD2) for the tumor was 111.3 Gy, reflecting the high biological effectiveness of the treatment. Conclusions. CT-guided high-dose-rate (HDR) brachytherapy represents a promising treatment approach for prostate cancer in cases where ultrasound guidance is not feasible, enabling high-dose delivery to the tumor while maintaining an acceptable toxicity profile.
- 31 March 2026
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 34 (1)
Open AccessCT-guided interstitial high-dose-rate brachytherapy of the prostate: a clinical case
Background. Prostate cancer is characterized by a low α/β ratio, supporting the use of hypofractionated treatment regimens, particularly high-dose-rate (HDR) brachytherapy. However, the application of CT guidance in this setting remains limited and technically challenging. Purpose. – the aim of this study is to present a case of non-standard high-dose- rate (HDR) prostate brachytherapy in a patient with absence of the rectum. Materials and Methods. We present a clinical case of a patient born in 1975 with metachronous malignancies: prostate cancer cT2N0M0 (stage II, Gleason score 4+5=9) on the background of previously treated stage III colorectal cancer following multi- modal therapy. Multiparametric MRI demonstrated multifocal PI-RADS 4 lesions. Interstitial high-dose-rate (HDR) brachytherapy was delivered as a single-fraction treatment (19 Gy) to the entire prostate using 14 applicators under CT guidance. Results. Adequate PTV coverage was achieved (D90 = 19.7 Gy, D95 = 17.3 Gy) with compliance to dose constraints for organs at risk (urethra D2cc = 18 Gy, <95%). The calculated equivalent dose in 2 Gy fractions (EQD2) for the tumor was 111.3 Gy, reflecting the high biological effectiveness of the treatment. Conclusions. CT-guided high-dose-rate (HDR) brachytherapy represents a promising treatment approach for prostate cancer in cases where ultrasound guidance is not feasible, enabling high-dose delivery to the tumor while maintaining an acceptable toxicity profile.